Browsing by Author Browett, Peter

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 8 of 8
Issue DateTitleAuthor(s)Citation
2012All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)Bradstock, Kenneth; Hertzberg, Mark; Iland, Harry; Browett, Peter; Catalano, Alberto; Collins, Marnie; Dilulio, J.; et al, various; Firkin, Frank; Grigg, Andrew P.; Hugman, Amanda; Reynolds, John; Supple, Shane; Tiley, Campbell; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Medicine (Westmead); Central Clinical School: MedicineAll-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4), Blood, vol.120, 8, 2012,pp 1570-1580
2003Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly disgnosed chronic myeloid leukemia in chronic phaseBradstock, Kenneth; Arthur, C.; Branford, Susan; Browett, Peter; Durrant, Simon; Gathmann, I.; Grigg, Andrew P.; Harper, A.; Hughes, T. P.; Joske, D.; Lynch, Kevin; Ma, D.; Rudzki, Zbigniew; Schwarer, Anthony; Seymour, John F.; Taylor, Kerry; Western Clinical School: Westmead Millennium InstituteImatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly disgnosed chronic myeloid leukemia in chronic phase, Leukemia, vol.17,(12),2003,pp 2401-2409
2015Inhibition of glutamate regulated calcium entry into leukemic megakaryoblasts reduces cell proliferation and supports differentiationMorel-Kopp, Marie-Christine; Ward, Christopher; Bohlander, Stefan; Browett, Peter; During, Matthew; Green, Taryn; Josefsson, Emma C; Kalev-Zylinska, Maggie; Kamal, Tania; McGlashan, Susan; McGregor, Ailsa; Skerry, Timothy; Teague, Lochie; Northern Clinical School: Medicine; Northern Clinical School: Kolling InstituteInhibition of glutamate regulated calcium entry into leukemic megakaryoblasts reduces cell proliferation and supports differentiation, Cellular Signalling, vol.27, 9, 2015,pp 1860-1872
2004Interferon-Alpha-2B And Oral Cytarabine Ocfosfate For Newly Diagnosed Chronic Myeloid Leukaemia.Arthur, Chris; Bradstock, Kenneth; Gibson, John; Browett, Peter; et, al; Grigg, Andrew P.; Hughes, T.; Januszewicz, H.; Mollee, P.; Schwarer, Anthony; Spencer, A.; Wolf, Max; Northern Clinical School: Medicine; Western Clinical School: Westmead Millennium Institute; Central Clinical School: MedicineInterferon-Alpha-2B And Oral Cytarabine Ocfosfate For Newly Diagnosed Chronic Myeloid Leukaemia., Annals of Oncology, vol.15,(12),2004,pp 1810-1815
2017Massive parallel sequencing of solid tumours - challenges and opportunities for pathologistsO'Toole, Sandra; Browett, Peter; George, Peter; Harris, Gavin; Print, Cristin; Central Clinical School: PathologyMassive parallel sequencing of solid tumours - challenges and opportunities for pathologists, Histopathology, vol.70, N/A, 2017,pp 123-133
2004Real-Time Quantitative Pcr Analysis Can Be Used As A Primary Screen To Identify Patients With Cml Treated With Imatinib Who Have Bcr-Abl Kinase Domain Mutations.Bradstock, Kenneth; Branford, Susan; Browett, Peter; Durrant, Simon; et, al; Grigg, Andrew P.; Parkinson, Ian; Rudzki, Zbigniew; Schwarer, Anthony; Seymour, John F.; Taylor, Kerry; Western Clinical School: Westmead Millennium InstituteReal-Time Quantitative Pcr Analysis Can Be Used As A Primary Screen To Identify Patients With Cml Treated With Imatinib Who Have Bcr-Abl Kinase Domain Mutations., Blood, vol.104,(9),2004,pp 2926-2932
2012Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemiaBradstock, Kenneth; Hertzberg, Mark; Iland, Harry; Brighton, Tim; Browett, Peter; Cannell, P; Catalano, J; Deveridge, Sandra; et al, various; Grigg, A; Horvath, Noemi; Seymour, John F.; Taylor, Kerry; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Medicine (Westmead); Central Clinical School: MedicineResults of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia, Haematologica: the hematology journal, vol.97, 2, 2012,pp 227-234
2015Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trialBradstock, Kenneth; Hertzberg, Mark; Iland, Harry; Browett, Peter; Campbell, Lynda J.; Catalano, Alberto; Collins, Marnie; Di Iulio, Juliana L.; et al, Various; Firkin, Frank; Grigg, Andrew P.; Hugman, Amanda; Reynolds, John; Supple, Shane; Western Clinical School: Westmead Institute for Medical Res; Western Clinical School: Medicine (Westmead); Central Clinical School: MedicineUse of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial, The Lancet Haematology, vol.2, 9, 2015,pp e357-e366